The current work examined the potential of using ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant moreover palbociclib. ARV-825 was effective in the two p53 wild-style (WT) breast tumor cells As well as in cells missing purposeful p53 possibly alone or in combination wit